PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
72.63%
Positive EBIT growth while CRON.TO is negative. John Neff might see a substantial edge in operational management.
72.63%
Positive operating income growth while CRON.TO is negative. John Neff might view this as a competitive edge in operations.
73.70%
Positive net income growth while CRON.TO is negative. John Neff might see a big relative performance advantage.
80.46%
Positive EPS growth while CRON.TO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
80.46%
Positive diluted EPS growth while CRON.TO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
33.82%
Share count expansion well above CRON.TO's 25.88%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
33.82%
Diluted share count expanding well above CRON.TO's 25.88%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
94.18%
OCF growth under 50% of CRON.TO's 234.45%. Michael Burry might suspect questionable revenue recognition or rising costs.
94.18%
FCF growth similar to CRON.TO's 94.16%. Walter Schloss would attribute it to parallel capital spending and operational models.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-35.39%
Firm’s AR is declining while CRON.TO shows 23.99%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
No Data
No Data available this quarter, please select a different quarter.
-4.88%
Negative asset growth while CRON.TO invests at 1.85%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-31.47%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-72.63%
We cut SG&A while CRON.TO invests at 8.16%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.